Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IPSC
- Price
- 0.48
- Stock movement up
- +0.07 (17.70%)
- Company name
- Century Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 40.81M
- Ent value
- 181.15M
- Price/Sales
- 15.20
- Price/Book
- 0.21
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -87.30%
- 3 year return
- -65.77%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IPSC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.20 |
| Price to Book | 0.21 |
| EV to Sales | 67.47 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 85.03M |
| EPS (TTM) | -1.53 |
| FCF per share (TTM) | -1.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.69M |
| Gross profit (TTM) | -10.85M |
| Operating income (TTM) | -132.25M |
| Net income (TTM) | -129.89M |
| EPS (TTM) | -1.53 |
| EPS (1y forward) | -1.83 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -404.17% |
| Operating margin (TTM) | -4925.59% |
| Profit margin (TTM) | -4837.73% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 52.59M |
| Net receivables | 1.35M |
| Total current assets | 206.01M |
| Goodwill | 4.73M |
| Intangible assets | 33.80M |
| Property, plant and equipment | 126.85M |
| Total assets | 388.62M |
| Accounts payable | 2.60M |
| Short/Current long term debt | 54.60M |
| Total current liabilities | 19.82M |
| Total liabilities | 192.93M |
| Shareholder's equity | 195.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -112.14M |
| Capital expenditures (TTM) | 2.59M |
| Free cash flow (TTM) | -114.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -66.38% |
| Return on Assets | -33.42% |
| Return on Invested Capital | -65.13% |
| Cash Return on Invested Capital | -57.52% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.42 |
| Daily high | 0.48 |
| Daily low | 0.41 |
| Daily Volume | 456K |
| All-time high | 31.93 |
| 1y analyst estimate | 9.67 |
| Beta | 1.42 |
| EPS (TTM) | -1.53 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| IPSC | S&P500 | |
| Current price drop from All-time high | -98.50% | -12.89% |
| Highest price drop | -98.78% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -75.74% | -11.07% |
| Avg time to new high | 96 days | 12 days |
| Max time to new high | 920 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
40.81M
Marketcap category
Small-cap
Description
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Employees
152
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page